AntNano Plc is a biological and chemical air quality analysis company specialising in the detection of hazardous materials using proprietary nanotechnology solutions Dr Allan Syms Chief Executive Officer April 2009 STRICTLY CONFIDENTIAL

AntNano Plc is a biological and chemical air quality analysis company specialising in the detection of hazardous materials using proprietary nanotechnology solutions

Dr Allan Syms

Chief Executive Officer April 2009

STRICTLY CONFIDENTIAL This presentation has been issued in connection with a proposed placing (the “Placing”) of new ordinary shares in AntNano plc (the “Company”). The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. The information in this presentation is subject to updating, completion, revision, further verification and amendment without notice. No assurance is given by the Company that any ordinary shares of the Company will be sold in the Placing. This presentation does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company, nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, or act as an inducement to enter into any contract or commitment therefore. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this presentation or any other document or oral statement, or on the completeness, accuracy or fairness of such information and/or opinions therein. No representation or warranty, express or implied, is made or given by or on behalf of the Company, any of their respective directors, or any other person as to the accuracy or completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any of them for such information or opinions or for any errors, omissions, misstatements, negligent or otherwise, or for any communication written or otherwise, contained or referred to in this presentation. DISCLAIMER

STRICTLY CONFIDENTIAL Accordingly, neither the Company nor any of their respective directors, officers, employees, advisers, associated persons or subsidiary undertakings shall be liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon the statement or as a result of any admission in, or any document supplied with, this presentation or by any future communications in connection with such documents and any such liabilities are expressly disclaimed. Prospective investors interested in investing in the Company are recommended to seek their own independent financial advice from a person authorised for the purposes of the Financial Services and Markets Act 2000. This presentation and its contents are confidential and should not be distributed, published or reproduced in whole or in part or disclosed by recipients to any other person. This presentation is not for distribution outside the United Kingdom and, in particular, should not be distributed to persons with addresses in Canada, Australia, Japan, Republic of Ireland, Republic of South Africa, or to persons with addresses in the United States of America, its territories or possession or to any citizen thereof or to any corporation, partnership or other entity created or organized under the laws thereof. Any such distribution could result in the violation of Canadian, Australian, Japanese, Irish, South African or United States of America law. The information in this presentation is confidential and must not be copied, reproduced or distributed to others at any time except for the purposes of analysis by certain employees and advisers of the recipient who have agreed to be bound by the restrictions contained herein. DISCLAIMER (cont.)

STRICTLY CONFIDENTIAL Originally created for Unilever and P&G to find better solutions for to detect airborne agents hazardous to human health: Address needs driven by legislation for controlling exposure Provide greater sensitivity in detecting hazardous materials (chemicals, biological agents, explosives) Real time analysis in the field or at the risk site Market Pull; Not Tech Push

Originally created for Unilever and P&G to find better solutions for to detect airborne agents hazardous to human health:

Address needs driven by legislation for controlling exposure

Provide greater sensitivity in detecting hazardous materials (chemicals, biological agents, explosives)

Real time analysis in the field or at the risk site

STRICTLY CONFIDENTIAL The Economic Argument Time Hrs Amortised Cost/test £ Existing Galley Sampler >150 64 New AntNano Dip Strips 4 30 AntNano Real Time Analyser 0.1 1.5

Real Time Air Analyser Airborne enzyme is captured by a cyclone Fluid passing through cyclone which transfers enzyme into liquid phase Enzyme solution passes through bioreactor Bioreactor substrate material is digested and fluorescent marker is released Fluorescence is measured and is proportional to enzyme concentration STRICTLY CONFIDENTIAL Cyclone Bioreactor Fluorimeter Fluid In Air In Air Out Waste

Airborne enzyme is captured by a cyclone

Fluid passing through cyclone which transfers enzyme into liquid phase

Enzyme solution passes through bioreactor

Bioreactor substrate material is digested and fluorescent marker is released

Fluorescence is measured and is proportional to enzyme concentration

STRICTLY CONFIDENTIAL High Volume Air Sampling Real Time Measurement Monitoring of Airborne Enzymes Current Product Range

STRICTLY CONFIDENTIAL Route to Market Group is a world leader in static airborne industrial enzyme monitoring (via Newton) 600 installations worldwide that presents immediate access for real-time analysers, bioreactors, and dip strips Currently established in the detergent industry – horizontal marketing segments such as food and beverage, tannery, paper and pulp, animal feed. Corporate partnerships and licensing – by combining new sensor technologies with existing air monitoring nanotechnologies for security and biomedical applications

Group is a world leader in static airborne industrial enzyme monitoring (via Newton)

600 installations worldwide that presents immediate access for real-time analysers, bioreactors, and dip strips

Currently established in the detergent industry – horizontal marketing segments such as food and beverage, tannery, paper and pulp, animal feed.

Corporate partnerships and licensing – by combining new sensor technologies with existing air monitoring nanotechnologies for security and biomedical applications

STRICTLY CONFIDENTIAL Customers Initially concentrating sales and marketing (Consortium members) Unilever Limited The Procter & Gamble Company Johnson Diversey Limited Novozymes A/S Industrial (Enzyme Detection) Oestrogen Steroid Detection Dioxin Detection Infectious Disease Detection Counter Terrorism Enzyme Manufacturers Manufacturers of Detergent Products Bakeries Pharmaceutical manufacturers Water authorities large scale manufacturing companies (e.g. cement factories) institutions with chimney stacks dioxin specific commercial laboratories governmental organizations environmental consultants. major global players hospitals and healthcare institutions for monitoring infectious diseases animal husbandry and farms military for rapid detection of biological agents. global partners Immigration Authority for explosives; and the military for detecting biological agents and improvised explosive devices.

Initially concentrating sales and marketing (Consortium members)

Unilever Limited

The Procter & Gamble Company

Johnson Diversey Limited

Novozymes A/S

Enzyme Manufacturers

Manufacturers of Detergent Products

Bakeries

Pharmaceutical manufacturers

Water authorities

large scale manufacturing companies (e.g. cement factories)

institutions with chimney stacks

dioxin specific commercial laboratories

governmental organizations

environmental consultants.

major global players

hospitals and healthcare institutions for monitoring infectious diseases

animal husbandry and farms

military for rapid detection of biological agents.

global partners

Immigration Authority for explosives; and

the military for detecting biological agents and improvised explosive devices.

STRICTLY CONFIDENTIAL Sustainable Advantages Products’ capabilities and advantages Inexpensive Rapid (a few minutes versus > a few days for lab-based analysis) Specific Sensitive Suitable for non-invasive testing Easy to use Company core competences and advantages Core team of experienced managers, research scientists and engineers in the application of nanotechnologies is a variety of markets Strong suite of patents and expected commercialisable new discoveries and novel inventions Providing real time analysis of airborne chemical and biological agents

Products’ capabilities and advantages

Inexpensive

Rapid (a few minutes versus > a few days for lab-based analysis)

Specific

Sensitive

Suitable for non-invasive testing

Easy to use

Company core competences and advantages

Core team of experienced managers, research scientists and engineers in the application of nanotechnologies is a variety of markets

Strong suite of patents and expected commercialisable new discoveries and novel inventions

Providing real time analysis of airborne chemical and biological agents

Heightened risk of chemical, explosive and biomedical threats Detection vital at airports, stadia, diplomatic conferences, other large public events and for protection of military personnel. Current technology involves differing detection systems Imaging: i.e. X-Ray of Terahertz. Chemical: Sensing i.e. IMS, Canine Olfaction Biomedical diagnostics e.g. PCR Technology limited either by: Access Sensitivity Speed Security Applications

Heightened risk of chemical, explosive and biomedical threats

Detection vital at airports, stadia, diplomatic conferences, other large public events and for protection of military personnel.

Current technology involves differing detection systems

Imaging: i.e. X-Ray of Terahertz.

Chemical: Sensing i.e. IMS, Canine Olfaction

Biomedical diagnostics e.g. PCR

Technology limited either by:

Access

Sensitivity

Speed

ANT Explosive Approach

Proven track record: Developed start-up companies to become self sustaining and quoted businesses, in bio and nanotechnology worth >£500m Directors have leveraged personal networks to develop business internationally Have personally guaranteed bank loans and leases for £200K Are a team with a blend of Commercial , Scientific and Financial skills STRICTLY CONFIDENTIAL Management

Proven track record:

Developed start-up companies to become self sustaining and quoted businesses, in bio and nanotechnology worth >£500m

Directors have leveraged personal networks to develop business internationally

Have personally guaranteed bank loans and leases for £200K

Are a team with a blend of Commercial , Scientific and Financial skills

Mr Joe Arend: Chairman Founder of AntNano and ex senior director of Proctor and Gamble, Rhone Poulenc. Founding member of successful start-ups Dr Allan Syms: Chief Executive Ex CEO of nanotechnology and sensor start-ups resulting in public listing Prof Fred Rowell: Chief Scientific Officer Founder of AntNano and renowned expert in nanotechnology and enzyme measurement Mr Alec Craig: Non-Executive Director Senior Partner of Halliwells LLP, Board member of VCT with key corporate governance skills Mr John Haworth: Non-Executive Director MD of Newton Instrument Group STRICTLY CONFIDENTIAL Management

Mr Joe Arend: Chairman

Founder of AntNano and ex senior director of Proctor and Gamble, Rhone Poulenc. Founding member of successful start-ups

Dr Allan Syms: Chief Executive

Ex CEO of nanotechnology and sensor start-ups resulting in public listing

Prof Fred Rowell: Chief Scientific Officer

Founder of AntNano and renowned expert in nanotechnology and enzyme measurement

Mr Alec Craig: Non-Executive Director

Senior Partner of Halliwells LLP, Board member of VCT with key corporate governance skills

Mr John Haworth: Non-Executive Director

MD of Newton Instrument Group

STRICTLY CONFIDENTIAL Financial Summary

STRICTLY CONFIDENTIAL Summary Formed in 2002 with investment of £254,000 from blue-chip consortium – Unilever, Proctor & Gamble, Novozymes and Genencor Subsequent investment in technology of ~£3m from shareholders, asset financing and grants 2007: Quoted on Plus Markets with current mkt cap ~ £6m 2007: £900K strategic alliance with NTU Singapore 2008: Acquired Newton Air Sampler Business 2008: Exclusive license to ultrasensitive microelectrode technology with option to acquire 2008: EDB Singapore RISC Grant ~£4.5 million 2008: POC grant NTU £90K infectious disease 2008: POC SPRING grant £115K new air sensors 2009: Products to market and seeking working capital

Formed in 2002 with investment of £254,000 from blue-chip consortium – Unilever, Proctor & Gamble, Novozymes and Genencor

Subsequent investment in technology of ~£3m from shareholders, asset financing and grants

2007: Quoted on Plus Markets with current mkt cap ~ £6m

2007: £900K strategic alliance with NTU Singapore

2008: Acquired Newton Air Sampler Business

2008: Exclusive license to ultrasensitive microelectrode technology with option to acquire

2008: EDB Singapore RISC Grant ~£4.5 million

2008: POC grant NTU £90K infectious disease

2008: POC SPRING grant £115K new air sensors

2009: Products to market and seeking working capital

STRICTLY CONFIDENTIAL Now seeking up to £1.0 m to fund: Sales and marketing expansion Bridge financial gap between suppliers and customers (working capital) Maintain IP protection Microarray Ltd strategic acquisition Investment Opportunity

Now seeking up to £1.0 m to fund:

Sales and marketing expansion

Bridge financial gap between suppliers and customers (working capital)

Maintain IP protection

Microarray Ltd strategic acquisition